HK Stock MarketDetailed Quotes

LIVZON PHARMA (01513)

Watchlist
  • 27.820
  • 0.0000.00%
Market to Open May 7 09:00 CST
24.70BMarket Cap11.11P/E (TTM)

LIVZON PHARMA (01513) Revenue Breakdown Overview

By Business/Source

Currency:CNY
2025/FY
Stock NameRevenueRatio
主营业务-化学制剂6.22B51.76%
主营业务-原料药和中间体3.12B25.93%
主营业务-中药制剂1.67B13.92%
主营业务-诊断试剂及设备656.9M5.46%
主营业务-生物制品200.8M1.67%
Other business-other75.39M0.63%
其他业务-销售材料、加工费等43.39M0.36%
Main business-other26.73M0.22%
其他业务-租赁费4.68M0.04%
View all

By Product

Currency:CNY
2025/FY
Stock NameRevenueRatio
主营业务-化学制剂6.22B51.76%
主营业务-原料药和中间体3.12B25.93%
主营业务-中药制剂1.67B13.92%
主营业务-诊断试剂及设备656.9M5.46%
主营业务-生物制品200.8M1.67%
Other business-other75.39M0.63%
其他业务-销售材料、加工费等43.39M0.36%
Main business-other26.73M0.22%
其他业务-租赁费4.68M0.04%
View all

By Country/Region

Currency:CNY
2025/FY
Stock NameRevenueRatio
Territory10.09B83.94%
Overseas1.93B16.06%

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Market Insights
China and the US begin implementing the Kuala Lumpur economic and trade consultation consensus.
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More